Replidyne Orapem Antibiotic Likely To Need Additional Trials Before Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Replidyne is conducting an additional Phase III trial of its oral beta-lactam antibiotic Orapem in anticipation of an FDA request for additional studies, according to the firm’s initial public offering prospectus.
You may also be interested in...
Replidyne commences Phase I for REP8839
Replidyne's topical anti-infective candidate REP8839 has begun Phase I studies, the firm says July 18. Replidyne, which recently filed an initial public offering registration statement, submitted an IND for the agent in May (1Pharmaceutical Approvals Monthly July 2006, p. 3)...